Last updated: 2026-09-14 09:49:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Quantum Biopharma Ltd (QNTM) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $3.22, with a market capitalization of $134.40 and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.07 to $21.00. This page covers its latest market performance, valuation, price trends and company information.
$134.40 | |
$3.24 | |
$38.25 | |
$2.07 | |
$3.20 | |
22.00 | |
185.43K | |
-- | |
$21.00 | |
$2.07 | |
-- | |
-- |
Quantum Biopharma Ltd (QNTM) is trading at $3.22 in pre-market trading as of 2026-09-14 08:02:00, up 0.50% ($0.02) from the previous close of $3.20
Pre-market trading shows how investors are pricing QNTM before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Quantum Biopharma Ltd (QNTM) moved from $3.08 to $3.22, representing a gain of 4.42% ($0.14).
The stock traded between $2.91 and $3.74 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 184.75 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 6.1%
QNTM is currently trading at $3.22, placing it 6.1% of the way from its 52-week low of $2.07 to its 52-week high of $21.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Quantum Biopharma Ltd (QNTM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.